Single-dose pharmacokinetics and safety of pegylated interferon-alpha2b in patients with chronic renal dysfunction. [electronic resource]
Producer: 20030213Description: 1109-15 p. digitalISSN:- 0091-2700
- Aged
- Antiviral Agents -- adverse effects
- Area Under Curve
- Female
- Hepatitis C -- prevention & control
- Humans
- Injections, Subcutaneous
- Interferon alpha-2
- Interferon-alpha -- adverse effects
- Kidney Failure, Chronic -- blood
- Male
- Metabolic Clearance Rate
- Middle Aged
- Polyethylene Glycols
- Recombinant Proteins
- Renal Dialysis
- Severity of Illness Index
No physical items for this record
Publication Type: Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.